Diabeloop, a young independent company
Creator of proprietary and pioneering diabetes management solutions, the Grenoble-based company works to make technological innovation available to all families living with Type 1 diabetes.
A three-fold expertise for a worldwide ambition
Drawing on its expertise in medical research, technology design and algorithms development, Diabeloop plans a progressive commercial roll-out while supporting an ambitious R&D roadmap.
Launch of the research program
Dr Guillaume Charpentier, diabetologist and CERITD’s chairman, initiates the medical research program alongside 12 other diabetologists.
Incorporation of Diabeloop SA
Incorporation of Diabeloop SA in Grenoble by Dr Charpentier and Erik Huneker; the company is co-headed by Marc Julien. Diabeloop and the CEA-Leti team up in one research facility to speed up the development of their medical device, the DBLG1 System.
Clinical trials
More than 150 patients have participated in several clinical trials.
Funding round
First public and private equity funding round with 13.5 million euros.
CE marking
November: Diabeloop announces a second funding round after obtaining the CE marking of its solution DBLG1 for adults.
Our ecosystem
Founders and CEOs
CERITD’s chairman and a leading specialist in diabetes, Dr. Guillaume Charpentier initiated the research program that led to Diabeloop creation. Co-founded with Erik Huneker, a Polytechnique engineer who succeeded in the medical device industry, the company is now headed by Erik Huneker and Marc Julien. The latter spent 25 years working for investment banks and VC companies and will facilitate the worldwide development of the company.
Technological
CEA-Leti is a tech research institute part of the CEA, specializing in micro and nano-technologies. A long-time partner of Diabeloop, it also shares a research laboratory with the company.
Medical
CERITD is a non-profit organization which aims at supporting research on diabetes. It led more than 50 clinical studies over the last 8 years and treated more than 1200 patients with the support of a vast network of healthcare professionals.
Medical centres
Since 2010, 12 public medical centers have been involved in various clinical studies with more than a 150 patients included. Today, Diabeloop develops new partnerships all across Europe, starting with Belgium and Luxembourg.
Board
Headed by Dr. Guillaume Charpentier, Diabeloop's board gathers its main investors: ALIAD, Supernova Invest, Sofimac Innovation, CERITD, Kreaxi.
Proud member of
